“…The proportions of patients receiving tofacitinib monotherapy ranged from 16.6-66.1%. [14][15][16][17][18][19][20][21][22][23][24] Where data were available, patients in these RWD analyses tended to be older and have lower baseline disease activity compared with patients in the clinical trials (Table 1). Patients had lower tender and swollen joint counts and were less likely to be bDMARD-naïve in the RWD analyses compared with the RCT and LTE studies (Table 1).…”